ストックスクリーナーアプリを入手
20.15
1.90%
-0.39
プレマーケット:
20.27
0.12
+0.60%
Castle Biosciences Inc (CSTL) 最新ニュース
How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets - Yahoo! Finance Canada
(CSTL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Castle Biosciences (CSTL) CEO reports planned stock sales and option exercises - Stock Titan
Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - MSN
Castle Biosciences, Inc. $CSTL Shares Sold by UBS Group AG - MarketBeat
Portolan Capital amends Castle Biosciences (NASDAQ: CSTL) 13G; 4.45% stake reported - Stock Titan
RTW Funds own 2.76M Castle Biosciences shares (CSTL) — 9.3% stake - Stock Titan
A Look at Castle Biosciences Inc (CSTL) After 4.1% Gain -- GF Va - GuruFocus
Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon - Investing.com
Castle Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-05-13 - Seeking Alpha
META_TITLE_QUOTE - Yahoo Finance
CSTL Maintained by BTIG -- Price Target Lowered to $40.00 - GuruFocus
BTIG lowers Castle Biosciences stock price target on higher costs By Investing.com - Investing.com India
BTIG Research Has Lowered Expectations for Castle Biosciences (NASDAQ:CSTL) Stock Price - MarketBeat
BTIG lowers Castle Biosciences stock price target on higher costs - Investing.com UK
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference - PR Newswire
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Bre - GuruFocus
Castle Biosciences recognized for driving progress in global healthcare with AdvanceAD-Tx accolade - Traders Union
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation - PR Newswire
Price-Driven Insight from (CSTL) for Rule-Based Strategy - Stock Traders Daily
TradingKey - TradingKey
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares By Investing.com - Investing.com Australia
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares - Investing.com India
Castle Biosciences (CSTL) CEO sells shares and exercises stock options in pre-planned trades - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Cut to "Sell" at Wall Street Zen - MarketBeat
Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 145.58% Upside Potential - DirectorsTalk Interviews
CSTL Achieves Strong Q1 Revenue, Raises 2026 Guidance - GuruFocus
CSTL Maintained by Baird -- Price Target Lowered to $43 - GuruFocus
Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL): Here's what you should know - MSN
Derek Maetzold files Form 144 to sell CSTL (NASDAQ: CSTL) shares - Stock Titan
Castle Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since July 2024 -- Data Talk - Moomoo
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down Following Analyst Downgrade - MarketBeat
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Castle Biosciences Q1 2026 slides: revenue beats, guidance raised By Investing.com - Investing.com Australia
Castle Biosciences (NASDAQ:CSTL) Price Target Lowered to $43.00 at Robert W. Baird - MarketBeat
Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders - MSN
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results, Hits Expectations - MarketBeat
Castle Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Castle Biosciences Q1 Earnings Call Highlights - MarketBeat
CSTL: Strong Q1 2026 results with raised guidance, record test volumes, and improved financials - TradingView
Castle (CSTL) Q1 2026 Earnings Transcript - AOL.com
Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth By Investing.com - Investing.com Australia
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Castle Biosciences Q1 2026 slides: revenue beats, guidance raised - Investing.com
0.72%
0.29%
大文字化:
|
ボリューム (24 時間):